Alpha Tau Reports Significant Clinical Progress in Q1
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy DRTS?
"The first quarter of 2026 has been a truly defining period for Alpha Tau, reflecting the convergence of two powerful dynamics that have been years in the making: the maturation of clinical data from our most advanced programs, and the global initiation of novel trials addressing some of the most pressing unmet needs in oncology," said Alpha Tau CEO Uzi Sofer. "The groundbreaking interim results from our U.S. REGAIN trial in recurrent glioblastoma, with 100% local disease control and a 67% complete response rate as of May 3, represent powerful potential clinical benefit in patients facing a devastating disease with virtually no curative options. Our pancreatic cancer program has also continued to build compelling data, first with positive new results from our Montreal study presented at the ASCO Gastrointestinal Cancers Symposium, then with the oral presentation of pooled pancreatic data at Digestive Disease Week 2026, and most recently with the expansion of our IMPACT pancreatic trial to include patients receiving gemcitabine with Abraxane."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DRTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DRTS
Wall Street analysts forecast DRTS stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.030
Low
5.00
Averages
7.00
High
9.00
Current: 10.030
Low
5.00
Averages
7.00
High
9.00
About DRTS
Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alpha Tau Medical Reports Wider Q1 Loss and Milestones
- Widening Financial Loss: Alpha Tau Medical reported a net loss of $22.9 million for Q1 2026, translating to $0.26 per share, which is a significant increase from last year's loss of $8.7 million or $0.12 per share, indicating heightened financial pressure during its clinical development phase that may affect future funding capabilities.
- Cash Reserves: As of March 31, 2026, the company had cash and cash equivalents totaling $80.2 million, which, while providing some liquidity, may not be sufficient to sustain operations and R&D efforts given the ongoing losses, necessitating careful cash management.
- Clinical Trial Updates: The firm anticipates completing patient recruitment for the IMPACT pancreatic cancer trial in Q3 2026 and plans to finish recruitment for the REGAIN recurrent GBM trial in the second half of 2026, with initial data expected by late 2026 or early 2027, which will be crucial for assessing the market potential of its therapies.
- Stock Performance Fluctuations: DRTS shares have traded between $2.81 and $10.81 over the past year, closing at $10.03 on Monday with a 3.19% decline, while pre-market trading shows a 3.09% increase to $10.34, reflecting market uncertainty regarding the company's future prospects.
See More
Alpha Tau Reports Q1 Loss Exceeding Estimates Amid Clinical Study Updates
- Disappointing Financials: Alpha Tau reported a net loss of $0.26 per share for Q1, surpassing Wall Street's estimate of a $0.12 loss, indicating increased financial pressure amid rising clinical trial activities.
- Clinical Trial Progress: The company expects to complete patient enrollment in its IMPACT pancreatic cancer pilot study in the U.S. during Q3, with initial data anticipated by late 2026 or early 2027, which could significantly impact its future market performance.
- R&D Spending Increase: Research and development expenses rose to $11 million from $7.2 million a year earlier, primarily driven by heightened clinical trial activities, which may affect short-term profitability but demonstrate the company's commitment to advancing its therapeutic pipeline.
- Strong Cash Position: As of the end of the quarter, Alpha Tau's cash, cash equivalents, short-term deposits, and restricted deposits totaled $80.2 million, providing robust funding support for clinical and commercial operations, even as market sentiment remains neutral.
See More
Alpha Tau Medical Reports Q1 2026 Financial Results
- Financial Performance: Alpha Tau Medical reported a GAAP EPS of -$0.26 for Q1 2026, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents, short-term deposits, and restricted deposits totaling $80.2 million, an increase from $76.9 million on December 31, 2025, suggesting improved liquidity management.
- Market Expectations: Analysts generally view 2026 as a breakthrough year for Alpha Tau Medical, and despite current financial struggles, the market remains optimistic about its future growth potential, which may attract long-term investor interest.
- Historical Financial Data: Historical earnings data for Alpha Tau Medical shows that the company has experienced fluctuations in financial performance, necessitating ongoing attention to its profitability and cash flow management to ensure sustainable growth.
See More
Alpha Tau Medical Announces Investor Conference Participation
- Investor Conference Schedule: Alpha Tau Medical's CFO Raphi Levy will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, engaging in a fireside chat and one-on-one meetings to enhance the company's visibility among investors.
- Event Timing and Location: The conference is scheduled for 10:30 to 11:00 AM ET in New York, followed by participation in the Rothschild & Co Redburn Radiopharma Conference on May 27 and the Lytham Partners Spring Investor Conference on May 28, further expanding investor relations.
- One-on-One Meeting Opportunities: Mr. Levy will be available for one-on-one investor meetings at all conferences, encouraging investors to schedule appointments through H.C. Wainwright, Rothschild, or Lytham Partners representatives to facilitate direct engagement with potential investors.
- Company Background: Founded in 2016, Alpha Tau Medical focuses on the research and development of Alpha DaRT®, aimed at effectively combating solid tumors through localized radiation therapy, showcasing its innovative potential in the oncology treatment landscape.
See More
Alpha Tau Medical Reports Promising Trial Results for Glioblastoma Treatment
- Clinical Trial Results: In the U.S. REGAIN trial, two of the three patients achieved complete responses, with MRI scans confirming the disappearance of all visible tumor lesions, while the third patient showed a 30% reduction in tumor size, indicating Alpha DaRT's potential in treating recurrent glioblastoma.
- Safety Assessment: As of May 3, 2026, Alpha Tau reported no unexpected serious adverse events, although one patient experienced a treatment-related seizure, which was resolved with steroid treatment, supporting the safety profile of the therapy.
- Positive Market Reaction: Shares of Alpha Tau Medical (DRTS) surged over 20% in pre-market trading on Monday, and if this level holds at market open, DRTS stock would reach its highest levels since August 2022, reflecting optimistic market sentiment towards the clinical data.
- Expanded Trial Plans: The FDA recently approved the expansion of Alpha Tau Medical's IMPACT pancreatic cancer trial testing Alpha DaRT in combination with chemotherapy, aimed at evaluating the therapy's safety and tolerability while monitoring tumor response and survival outcomes, showcasing the company's ongoing innovation in cancer treatment.
See More
Alpha Tau Medical Shares Surge 12% on Positive Glioblastoma Trial Results
- Clinical Trial Progress: Alpha Tau Medical's REGAIN trial for recurrent glioblastoma has reported encouraging interim results, with two out of three treated patients achieving complete response, indicating the therapy's efficacy and safety as all enhancing tumor lesions disappeared on multiple post-treatment MRI scans.
- Strong Market Reaction: Following the interim results, Alpha Tau's shares surged over 12% in premarket trading to $9.60, reflecting increased investor confidence in the company's treatment approach, which may drive future capital inflows.
- Survival Rate Challenges: Glioblastoma is the most common and aggressive form of brain cancer, with an average survival rate of only 8 months, while the REGAIN trial aims to treat 10 patients, showcasing the company's potential in addressing this complex disease.
- Optimistic Strategic Outlook: Chief Medical Officer Robert Den expressed gratification at the interim results, especially given the typical survival of under 12 months post-recurrence, providing strong rationale to advance the trial, potentially paving the way for future clinical applications.
See More
Alpha Tau Medical Reports Wider Q1 Loss and Milestones
- Widening Financial Loss: Alpha Tau Medical reported a net loss of $22.9 million for Q1 2026, translating to $0.26 per share, which is a significant increase from last year's loss of $8.7 million or $0.12 per share, indicating heightened financial pressure during its clinical development phase that may affect future funding capabilities.
- Cash Reserves: As of March 31, 2026, the company had cash and cash equivalents totaling $80.2 million, which, while providing some liquidity, may not be sufficient to sustain operations and R&D efforts given the ongoing losses, necessitating careful cash management.
- Clinical Trial Updates: The firm anticipates completing patient recruitment for the IMPACT pancreatic cancer trial in Q3 2026 and plans to finish recruitment for the REGAIN recurrent GBM trial in the second half of 2026, with initial data expected by late 2026 or early 2027, which will be crucial for assessing the market potential of its therapies.
- Stock Performance Fluctuations: DRTS shares have traded between $2.81 and $10.81 over the past year, closing at $10.03 on Monday with a 3.19% decline, while pre-market trading shows a 3.09% increase to $10.34, reflecting market uncertainty regarding the company's future prospects.
See More
Alpha Tau Reports Q1 Loss Exceeding Estimates Amid Clinical Study Updates
- Disappointing Financials: Alpha Tau reported a net loss of $0.26 per share for Q1, surpassing Wall Street's estimate of a $0.12 loss, indicating increased financial pressure amid rising clinical trial activities.
- Clinical Trial Progress: The company expects to complete patient enrollment in its IMPACT pancreatic cancer pilot study in the U.S. during Q3, with initial data anticipated by late 2026 or early 2027, which could significantly impact its future market performance.
- R&D Spending Increase: Research and development expenses rose to $11 million from $7.2 million a year earlier, primarily driven by heightened clinical trial activities, which may affect short-term profitability but demonstrate the company's commitment to advancing its therapeutic pipeline.
- Strong Cash Position: As of the end of the quarter, Alpha Tau's cash, cash equivalents, short-term deposits, and restricted deposits totaled $80.2 million, providing robust funding support for clinical and commercial operations, even as market sentiment remains neutral.
See More
Alpha Tau Medical Reports Q1 2026 Financial Results
- Financial Performance: Alpha Tau Medical reported a GAAP EPS of -$0.26 for Q1 2026, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents, short-term deposits, and restricted deposits totaling $80.2 million, an increase from $76.9 million on December 31, 2025, suggesting improved liquidity management.
- Market Expectations: Analysts generally view 2026 as a breakthrough year for Alpha Tau Medical, and despite current financial struggles, the market remains optimistic about its future growth potential, which may attract long-term investor interest.
- Historical Financial Data: Historical earnings data for Alpha Tau Medical shows that the company has experienced fluctuations in financial performance, necessitating ongoing attention to its profitability and cash flow management to ensure sustainable growth.
See More
Alpha Tau Medical Announces Investor Conference Participation
- Investor Conference Schedule: Alpha Tau Medical's CFO Raphi Levy will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, engaging in a fireside chat and one-on-one meetings to enhance the company's visibility among investors.
- Event Timing and Location: The conference is scheduled for 10:30 to 11:00 AM ET in New York, followed by participation in the Rothschild & Co Redburn Radiopharma Conference on May 27 and the Lytham Partners Spring Investor Conference on May 28, further expanding investor relations.
- One-on-One Meeting Opportunities: Mr. Levy will be available for one-on-one investor meetings at all conferences, encouraging investors to schedule appointments through H.C. Wainwright, Rothschild, or Lytham Partners representatives to facilitate direct engagement with potential investors.
- Company Background: Founded in 2016, Alpha Tau Medical focuses on the research and development of Alpha DaRT®, aimed at effectively combating solid tumors through localized radiation therapy, showcasing its innovative potential in the oncology treatment landscape.
See More
Alpha Tau Medical Reports Promising Trial Results for Glioblastoma Treatment
- Clinical Trial Results: In the U.S. REGAIN trial, two of the three patients achieved complete responses, with MRI scans confirming the disappearance of all visible tumor lesions, while the third patient showed a 30% reduction in tumor size, indicating Alpha DaRT's potential in treating recurrent glioblastoma.
- Safety Assessment: As of May 3, 2026, Alpha Tau reported no unexpected serious adverse events, although one patient experienced a treatment-related seizure, which was resolved with steroid treatment, supporting the safety profile of the therapy.
- Positive Market Reaction: Shares of Alpha Tau Medical (DRTS) surged over 20% in pre-market trading on Monday, and if this level holds at market open, DRTS stock would reach its highest levels since August 2022, reflecting optimistic market sentiment towards the clinical data.
- Expanded Trial Plans: The FDA recently approved the expansion of Alpha Tau Medical's IMPACT pancreatic cancer trial testing Alpha DaRT in combination with chemotherapy, aimed at evaluating the therapy's safety and tolerability while monitoring tumor response and survival outcomes, showcasing the company's ongoing innovation in cancer treatment.
See More
Alpha Tau Medical Shares Surge 12% on Positive Glioblastoma Trial Results
- Clinical Trial Progress: Alpha Tau Medical's REGAIN trial for recurrent glioblastoma has reported encouraging interim results, with two out of three treated patients achieving complete response, indicating the therapy's efficacy and safety as all enhancing tumor lesions disappeared on multiple post-treatment MRI scans.
- Strong Market Reaction: Following the interim results, Alpha Tau's shares surged over 12% in premarket trading to $9.60, reflecting increased investor confidence in the company's treatment approach, which may drive future capital inflows.
- Survival Rate Challenges: Glioblastoma is the most common and aggressive form of brain cancer, with an average survival rate of only 8 months, while the REGAIN trial aims to treat 10 patients, showcasing the company's potential in addressing this complex disease.
- Optimistic Strategic Outlook: Chief Medical Officer Robert Den expressed gratification at the interim results, especially given the typical survival of under 12 months post-recurrence, providing strong rationale to advance the trial, potentially paving the way for future clinical applications.
See More
